BAC
Bank of America Corporation
BAC has lower modeled downside risk, despite its lower overall score.
UVE
Universal Insurance Holdings, Inc.
UVE has the edge over BAC overall, supported by stronger valuation and stronger fundamentals.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
UVE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
UVE's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like UVE.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
UVE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 6.1x | $48.57 | — |
| Cheap | 7x | $55.89 | +15% |
| Fair | 10x | $82.24 | +69% |
| Forward | 13x | $48.57 | — |
| Expensive | 24x | $195 | +302% |
Historical ranges are pointers, not guarantees.
UVE has the edge over BAC in the historical PE scenario, which offers more potential upside but is not a forecast.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over UVE on the outlook, with more favorable valuation and earnings expectations.
UVE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect UVE's earnings and profitability to decline, with its revenue holding steady.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC's earnings per share have climbed steadily: $4.19 over the past year, up 14% from the year before, and higher year over year for eight quarters in a row.
UVE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.88 | -51% |
| Q3 2026 | $8.00 | +89% |
| Q2 2026 | $7.58 | +231% |
| Q1 2026 | $6.75 | +195% |
| Q4 2025 | $6.31 | +217% |
| Q3 2025 | $4.24 | +72% |
| Q2 2025 | $2.29 | -19% |
| Q1 2025 | $2.29 | -10% |
| Q4 2024 | $1.99 | -9.5% |
UVE earned $8.00 per share over the past year, up 89% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over UVE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC has the edge over UVE on profitability, with a higher operating margin.
UVE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $439.3M | +9.6% |
| Q2 2026 | $427M | +6.7% |
| Q1 2026 | $393.6M | -0.3% |
| Q4 2025 | $407.9M | +6% |
| Q3 2025 | $401M | +3.5% |
| Q2 2025 | $400.1M | +5.2% |
| Q1 2025 | $394.9M | +7.3% |
| Q4 2024 | $384.8M | +2.5% |
UVE's revenue is growing: $439M last quarter, up 9.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | +2.8 points |
| Q2 2026 | 19% | +7.1 points |
| Q1 2026 | 18% | +4.2 points |
| Q4 2025 | 22% | +20 points |
| Q3 2025 | 13% | +18 points |
| Q2 2025 | 12% | -1 points |
| Q1 2025 | 14% | +1.1 points |
| Q4 2024 | 1.9% | -5 points |
UVE's operating margin was 16% last quarter, up 2.8 points from the same quarter a year ago.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
UVE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $82M | +34% |
| Q2 2026 | $100.2M | -4.8% |
| Q1 2026 | $153.2M | -17% |
| Q4 2025 | $25M | +$127.2M |
| Q3 2025 | $61.3M | -24% |
| Q2 2025 | $105.2M | +47% |
| Q1 2025 | $185.5M | +133% |
| Q4 2024 | -$102.2M | -$101.4M |
UVE's free cash flow was $360M over the past year, up 44% from the year before. Free cash flow isn't a meaningful measure for financial services companies like UVE.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over UVE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
UVE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +142K shares |
| 1 year | +1.3% | +377K shares |
| 3 years | -1.5% | -432K shares |
| 5 years | -6.9% | -2.2M shares |
| Available history | -15% | -5M shares |
UVE has 29M diluted shares, up 1.3% from a year ago, despite $26M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $7.5M |
| Q2 2026 | $4.5M |
| Q1 2026 | $7.1M |
| Q4 2025 | $6.9M |
| Q3 2025 | $8.1M |
| Q2 2025 | $7.4M |
| Q1 2025 | — |
| Q4 2024 | $7.7M |
UVE spent $26M buying back its own shares over the past year, up 12% from the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
UVE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
| Q2 2026 | -1.5x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q4 2025 | -1.3x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -2.9x | Net Cash |
| Q1 2025 | -3.2x | Net Cash |
| Q4 2024 | -1.9x | Net Cash |
UVE has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
UVE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.3 | Neutral |
| Stochastic | 69.2 | Neutral |
UVE's weekly RSI is 66 (neutral) and its Stochastic is 69 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
UVE PE vs Financial Services Sector
| Metric | UVE | Sector median | Relative |
|---|---|---|---|
| PE | 6.1x | 13x | 53% below |
| PE % | 10 | 63 | 53 pts below |
UVE has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
UVE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.5 | 4.5% above |
| 20 week MA | $44.3 | 9.5% above |
| 50 week MA | $38.5 | 26% above |
| 100 week MA | $31.7 | 53% above |
| 200 week MA | $24.6 | 98% above |
UVE has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
UVE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.0 | $14.8 | -47% |
| 2021 | $14.8 | $16.8 | +14% |
| 2022 | $16.8 | $11.0 | -35% |
| 2023 | $11.0 | $16.0 | +46% |
| 2024 | $16.0 | $20.6 | +29% |
| 2025 | $20.6 | $33.8 | +64% |
| 2026 YTD | $33.8 | $48.6 | +44% |
UVE has the edge over BAC on returns for 2026, with the stronger performance.